Shedir Pharma Srl Unipersonale
MIL:SHE

Watchlist Manager
Shedir Pharma Srl Unipersonale Logo
Shedir Pharma Srl Unipersonale
MIL:SHE
Watchlist
Price: 4.86 EUR Market Closed
Market Cap: 55.5m EUR
Have any thoughts about
Shedir Pharma Srl Unipersonale?
Write Note

Shedir Pharma Srl Unipersonale
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shedir Pharma Srl Unipersonale
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Shedir Pharma Srl Unipersonale
MIL:SHE
Operating Income
€8.5m
CAGR 3-Years
10%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Newron Pharmaceuticals SpA
SIX:NWRN
Operating Income
-€15m
CAGR 3-Years
2%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
Operating Income
€637.4m
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
11%
P
Pierrel SpA
MIL:PRL
Operating Income
€3.5m
CAGR 3-Years
-5%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Friulchem SpA
MIL:FCM
Operating Income
€592.9k
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
N/A
No Stocks Found

Shedir Pharma Srl Unipersonale
Glance View

Market Cap
55.2m EUR
Industry
Pharmaceuticals

Shedir Pharma Group SpA operates as a holding company which engages in the research and development of nutraceuticals and medical devices. The company is headquartered in Mercato San Severino, Salerno and currently employs 71 full-time employees. The company went IPO on 2019-07-23. The firm markets its products in different forms and under the brand lines Shedir Farmaceutici, Deimos Farmaceutici, Phobos Farmaceutici, Menkar Farmaceutici and Greenplanet Divisione Farmaceutica. Its products cover a wide range of therapeutics areas, such as cardiovascular, dermatology, neurology, urology, gynecology and dental health, among others.

SHE Intrinsic Value
7.59 EUR
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Shedir Pharma Srl Unipersonale's Operating Income?
Operating Income
8.5m EUR

Based on the financial report for Dec 31, 2023, Shedir Pharma Srl Unipersonale's Operating Income amounts to 8.5m EUR.

What is Shedir Pharma Srl Unipersonale's Operating Income growth rate?
Operating Income CAGR 5Y
-2%

Over the last year, the Operating Income growth was 4%. The average annual Operating Income growth rates for Shedir Pharma Srl Unipersonale have been 10% over the past three years , -2% over the past five years .

Back to Top